GlassScriptPhysician profile
Michael J Lucke
NPI 1225264336
$50,804.07
in general payments reported to CMS, 2019-2025
15 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $5,308 · 2021: $52.88 · 2022: $2,690 · 2023: $4,621 · 2024: $5,595 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $2,823 · Travel and Lodging: $2,550 · Consulting Fee: $1,150 · Education: $24.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,937.50 |
| Food and Beverage | $2,822.50 |
| Travel and Lodging | $2,549.57 |
| Consulting Fee | $1,150.00 |
| Education | $24.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41,243.83 | 2019-2025 | Uplizna, Tavneos, Enbrel |
| Abbvie INC. | $6,544.96 | 2020-2025 | |
| Ucb, INC. | $1,129.66 | 2019-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $716.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $263.47 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $212.48 | 2019-2025 | Benlysta |
| Pfizer INC. | $199.95 | 2022-2025 | |
| Janssen Biotech, INC. | $140.85 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $111.40 | 2019 | |
| Aurinia Pharma U.S., INC. | $97.73 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $47.35 | 2023-2024 | Taltz |
| Sobi, INC | $33.17 | 2024 | |
| Celltrion USA INC. | $24.74 | 2024 | Zymfentra |
| Invivyd INC | $22.79 | 2024 | Pemgarda |
| Kiniksa Pharmaceuticals, LTD. | $14.84 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lucke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.